NextCure (NXTC) Competitors $0.45 -0.01 (-2.17%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.44 -0.01 (-2.89%) As of 06/27/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. TELO, AADI, CNTX, ANVS, RNXT, AVTX, IPSC, KLTO, VTVT, and BLUEShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Telomir Pharmaceuticals (TELO), Aadi Bioscience (AADI), Context Therapeutics (CNTX), Annovis Bio (ANVS), RenovoRx (RNXT), Avalo Therapeutics (AVTX), Century Therapeutics (IPSC), Klotho Neurosciences (KLTO), vTv Therapeutics (VTVT), and bluebird bio (BLUE). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Telomir Pharmaceuticals Aadi Bioscience Context Therapeutics Annovis Bio RenovoRx Avalo Therapeutics Century Therapeutics Klotho Neurosciences vTv Therapeutics bluebird bio NextCure (NASDAQ:NXTC) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Do insiders and institutionals believe in NXTC or TELO? 42.7% of NextCure shares are held by institutional investors. 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, NXTC or TELO? NextCure has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500. Is NXTC or TELO more profitable? NextCure's return on equity of -70.16% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -70.16% -58.10% Telomir Pharmaceuticals N/A -2,009.40%-1,009.72% Does the media refer more to NXTC or TELO? In the previous week, NextCure had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for NextCure and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.87 beat NextCure's score of 0.62 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NextCure Positive Telomir Pharmaceuticals Very Positive Do analysts rate NXTC or TELO? NextCure currently has a consensus target price of $3.50, indicating a potential upside of 677.78%. Telomir Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 880.39%. Given Telomir Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger valuation and earnings, NXTC or TELO? Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$55.65M-$1.76-0.26Telomir PharmaceuticalsN/AN/A-$16.53M-$0.42-3.64 SummaryNextCure beats Telomir Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.62M$2.84B$5.46B$8.92BDividend YieldN/A2.70%5.35%4.14%P/E Ratio-0.2620.8926.1519.64Price / SalesN/A281.81410.74112.88Price / CashN/A41.2925.7827.49Price / Book0.197.197.875.41Net Income-$55.65M-$55.05M$3.16B$248.99M7 Day Performance-4.26%0.76%3.10%3.99%1 Month Performance-9.35%4.39%4.62%4.82%1 Year Performance-71.70%-0.74%31.74%17.00% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.3699 of 5 stars$0.45-2.2%$3.50+677.8%-71.7%$12.62MN/A-0.2690Gap UpTELOTelomir Pharmaceuticals2.9865 of 5 stars$1.69-4.0%$15.00+787.6%-68.2%$52.38MN/A-4.021AADIAadi Bioscience0.6022 of 5 stars$2.09+2.0%$1.67-20.3%+32.2%$51.62M$25.07M-0.9240High Trading VolumeCNTXContext Therapeutics3.4531 of 5 stars$0.56-1.6%$6.00+965.0%-67.2%$51.37MN/A-1.827News CoverageAnalyst ForecastANVSAnnovis Bio1.9306 of 5 stars$2.64+1.5%$30.25+1,045.8%-63.3%$50.66MN/A-1.223RNXTRenovoRx3.0316 of 5 stars$1.41+2.2%$7.25+414.2%+13.3%$50.47M$40K-3.536Gap DownHigh Trading VolumeAVTXAvalo Therapeutics3.1872 of 5 stars$4.79+3.2%$30.00+526.3%-61.7%$50.24M$440K0.0040IPSCCentury Therapeutics2.6099 of 5 stars$0.58-1.2%$4.20+630.4%-79.7%$50.14M$6.59M-1.98170News CoverageKLTOKlotho NeurosciencesN/A$1.20-22.1%N/AN/A$50.04MN/A-3.33N/AGap DownVTVTvTv Therapeutics2.0305 of 5 stars$15.61+0.4%$35.50+127.5%-18.0%$49.66M$1.02M-5.189News CoverageBLUEbluebird bio3.124 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520 Related Companies and Tools Related Companies TELO Competitors AADI Competitors CNTX Competitors ANVS Competitors RNXT Competitors AVTX Competitors IPSC Competitors KLTO Competitors VTVT Competitors BLUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
